Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound

Bykov, Vladimir J.N., Issaeva, Natalia, Shilov, Alexandre, Hultcrantz, Monica, Pugacheva, Elena, Chumakov, Peter, Bergman, Jan, Wiman, Klas G. +1 more·2002·Nature Medicine
DOI 10.1038/nm0302-282

Cited by (1,000)

Items 801–900 of 1,000

  1. Advances on mutant p53 research
    Dahu Li · 2008 · Hereditas (Beijing)
  2. Role of p53 family isoforms in enhancing aggressiveness and chemoresistance in pancreatic cancer (Review)
    Hossein Jahedi, Aminath Luveysa Fahud, Chooi Ling Lim · 2019 · World Academy of Sciences Journal
  3. Design and Synthesis of Novel Inhibitor against Ser121 and Val122 Mutations in P53 Cancer Gene
    Muhammad Hamza, Azhar Mahmood, Sajid Ali Khan, Muhammad Rizwan, Anum Munir · 2019 · Advances in Pharmacology and Pharmacy
  4. Expression of Wild-Type p53 by Curcumin, Alpinetin and Flavokawain B in Colorectal Cancer cells Expressing R273H Mutant p53
    Ibrahim Malami, Aliyu Idris Muhammad, Ibrahim Babangida Abubakar, Alhassan Muhammad Alhassan · 2020 · Nigerian Journal of Basic and Applied Sciences
  5. Synergisms of genome and metabolism stabilizing antitumor therapy (GMSAT) in human breast and colon cancer cell lines: a novel approach to screen for synergism
    Jérôme Ruhnau, Jonas Parczyk, Kerstin Danker, Britta Johanna Eickholt, Andreas Klein · 2020 · BMC Cancer
  6. Harnessing Apoptosis in AML
    Kapil Saxena, Courtney Denton Dinardo, Naval Guastad Daver, Marina Y Konopleva · 2020 · Clinical Lymphoma Myeloma & Leukemia
  7. Oncoapoptotic Markers in Oral Cancer: Prognostics and Therapeutic Perspective
    Anubhav Jain, Saurabh Bundela, Ram Pramod Tiwari, Prakash Singh Bisen · 2014 · Molecular Diagnosis & Therapy
  8. The inhibition of tumor growth by triplex-forming oligonucleotides
    Richard N. Ré, Julia L. Cook, Jason F. Giardina · 2004 · Cancer Letters
  9. C-terminal peptides of p53 molecules enhance radiation-induced apoptosis in human mutant p53 cancer cells
    Ken Ohnishi, Hiroko Inaba, J. Yasumoto, Kazue Yuki, Akihisa Takahashi, Takeo Ohnishi · 2004 · APOPTOSIS
  10. Structure–activity studies of quinuclidinone analogs as anti-proliferative agents in lung cancer cell lines
    Ahmed M Malki, Aravinda B. Pulipaka, Susan C. Evans, Stephen C. Bergmeier · 2005 · Bioorganic & Medicinal Chemistry Letters
  11. RADIOPROTECTIVE ACTIVITY OF FICUS RACEMOSA ETHANOL EXTRACT AGAINST ELECTRON BEAM INDUCED DNA DAMAGE IN VITRO, IN VIVO AND IN SILICO
    K Vinutha, S. M. Vidya, Suchetha Kumari, Ganesh Sanjeev, Holenarasipur GunduRao Nagendra, Pradeepa, Vaman C. Rao · 2015 · International Journal of Pharmacy and Pharmaceutical Sciences
  12. Regulation of p53 DNA Binding
    Kristine M. McKinney, Carol L. Prives · 2005 · Springer eBooks
  13. Wild Type p53 Conformation, Structural Consequences of p53 Mutations and Mechanisms of Mutant p53 Rescue
    Andreas C. Joerger, Assaf Friedler, Alan Roy Fersht · 2007 · Springer eBooks
  14. TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA
    Ugo Testa, Germana Castelli, Elvira Pelosi · 2023 · Mediterranean Journal of Hematology and Infectious Diseases
  15. Side-stepping the guardian of the genome: current cancer therapeutics targeting mutant p53
    Iulianna C. Taritsa, Eric T. Fossel · 2025 · Frontiers in Pharmacology
  16. Hypoxic resistance of KRAS mutant tumor cells to 3-Bromopyruvate is counteracted by Prima-1 and reversed by N-acetylcysteine
    Andrea Orué, Valery A. Chavez, Mary Strasberg–Rieber, Manuel Rieber · 2016 · BMC Cancer
  17. Molecular genetic profiling reveals novel association between FLT3 mutation and survival in glioma
    Kevin Shee, Meagan Chambers, Edward G. Hughes, Damian A. Almiron Bonnin, Sophie J. Deharvengt, DONALD PHILIP GREEN, Joel A. Lefferts, Angeline S. Andrew, William F. Hickey, Gregory J. Tsongalis · 2020 · Journal of Neuro-Oncology
  18. TACIMA-218: A Novel Pro-Oxidant Agent Exhibiting Selective Antitumoral Activity
    Jamilah Abusarah, Yun Cui, Nehmé El-Hachem, Abed El-Hakim El-Kadiry, Ian Hammond-Martel, Hugo Würtele, Annie Beaudry, Noël J.‐M. Raynal, Francis Robert, Jerry Pelletier et al. · 2020 · Molecular Cancer Therapeutics
  19. Rare diseases of ectoderm: Translating discovery to therapy
    John Timothy Wright, Becky M. Abbott, Maddison N. Salois, Jessica A. Gugger, Shirley P. Parraga, Amanda K. Swanson, Mary D. Fete, Maranke I. Koster · 2022 · American Journal of Medical Genetics Part A
  20. The targeted next-generation sequence revealed SMAD4, AKT1, and TP53 mutations from circulating cell-free DNA of breast cancer and its effect on protein structure – A computational approach
    Ambritha Balasundaram, S. Udhaya Kumar, D. Thirumal Kumar, Aditi Anil Dedge, Gnanasambandan Ramanathan, Satish Srinivas Kondaveeti, Siva Ramamoorthy, C. George Priya Doss · 2023 · Journal of Biomolecular Structure and Dynamics
  21. The Therapeutic Potential of a Strategy to Prevent Acute Myeloid Leukemia Stem Cell Reprogramming in Older Patients
    Moon Nyeo Park · 2023 · International Journal of Molecular Sciences
  22. 2,2-Diphenethyl Isothiocyanate Enhances Topoisomerase Inhibitor-Induced Cell Death and Suppresses Multi-Drug Resistance 1 in Breast Cancer Cells
    Monika Aggarwal · 2023 · Cancers
  23. SOHO State of the Art Updates and Next Questions: Harnessing Apoptosis in AML
    Kapil Saxena, Courtney Denton Dinardo, Naval Guastad Daver, Marina Y Konopleva · 2021 · Clinical Lymphoma Myeloma & Leukemia
  24. In vitro folding and characterization of the p53 DNA binding domain
    Christian Klein, Friederike Hesse, Alexander Dehner, Richard Alan Engh, Markus Schwaiger, Silke Hansen · 2004 · Biological Chemistry
  25. Oncolytic viruses: a new paradigm for treatment of head and neck cancer
    John Bryan Lott · 2011 · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology
  26. Scintillation Proximity Assay for DNA Binding by Human p53
    Susannah Gal, Jeffery R. Cook, Leighton Howells · 2006 · BioTechniques
  27. Low p14ARF expression in de novo acute myeloid leukemia with normal karyotype is associated with poor survival
    Esbjörn Paul, Esbjörn Paul, Bertil Uggla, Stefan Deneberg, Sofia Bengtzén, Monica Hermansson, Ingrid A. Dahlman, Richard Rosenquist, Klas G. Wiman, Hareth Nahi · 2009 · Leukemia & lymphoma/Leukemia and lymphoma
  28. Hyperactive end joining repair mediates resistance to DNA damaging therapy in p53-deficient cells
    Rashmi J. Kumar, Hui Xiao Chao, Victoria Roberts, Aurora R Sullivan, Sonam Shah, Dennis A. Simpson, Wanjuan Feng, Anne‐Sophie Wozny, Sunil Kumar, Jeremy E. Purvis et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  29. PRIMA-1 synergizes olaparib-induced cell death in p53 mutant triple negative human breast cancer cell line via restoring p53 function, arresting cell cycle, and inducing apoptosis
    Mohamed Mahmoud Abdelfatah Zaza, Mohammed Helmy Rashed, Hesham El-Refaey, Memy H. Hassan, Osama M. Abo‐Salem, El-Sayed M. El-Sayed · 2023 · Canadian Journal of Physiology and Pharmacology
  30. BRAF V600E-induced distinct DNA damage response defines the therapeutic potential of p53 activation for TP53 wild-type colorectal cancer
    Shinji Tokuyama, Hisakazu Kato, Hidekazu Takahashi, Kyoko Ueda, Asami Arita, Ryuta Ueda, Hiroto Seto, Yuki Sekido, Tsuyoshi Hata, Atsushi Hamabe et al. · 2024 · Carcinogenesis
  31. The Apoptotic, Cytotoxic, and Anti-migration Effects of Sodium Deoxycholate in a Breast Cancer Cell Line and its Modulation on PON1 as a Predictive Risk Marker
    Yasin Tülüce, Huda Alhammud, Ahmet Yasin Keleş, Sedat Köstekci · 2024 · Current Molecular Medicine
  32. Combination therapy involving azacitidine for acute myeloid leukemia patients ineligible for intensive chemotherapy
    Juan Li, Shuying Fu, Chunmei Ye, Jun Li · 2024 · Leukemia Research
  33. Capturing Unicorns: Targeting Cancers With TP53 Mutations, RAS Alterations Beyond G12C, and MTAP Loss—No Target Is Out of the Realm of Possibility
    Pooja Anil Shah, Klas G. Wiman, Karen M. Cichowski, Jordi Ahnert Rodon · 2025 · American Society of Clinical Oncology Educational Book
  34. Targeting the p53/xCT/GSH Axis with PRIMA-1Met Combined with Sulfasalazine Shows Therapeutic Potential in Chronic Lymphocytic Leukemia
    Martina Pasino, Andrea Speciale, Silvia Ravera, Giovanna Cutrona, Rosanna Massara, Nadia Bertola, Maurizio Viale, Irena Velkova, Andrea Nicola Mazzarello, Franco Fais et al. · 2025 · International Journal of Molecular Sciences
  35. Tumorigenic p53 mutants undergo common structural disruptions including conversion to α‐sheet structure
    Dennis Bromley, Valerie Daggett · 2020 · Protein Science
  36. Myelodysplastic syndrome: Approach to diagnosis in the era of personalized medicine
    Paul Dylan Barone, Sanjay S. Patel · 2023 · Seminars in Diagnostic Pathology
  37. Current State and Future Prospects of Diagnosis and Management of TP53-Mutated Myeloid Neoplasms
    Sangeetha Venugopal, Sanam Loghavi · 2023 · Pathobiology
  38. Establishment of ganglioside GD2-expressing extranodal NK/T-cell lymphoma cell line with scRNA-seq analysis
    Ai Sato, Midori Ishii, Kota Tachibana, Yoshiki Furukawa, Tokuko Toyota, Shintaro Kinoshita, Yoko Azusawa, Jun Ando, Miki Ando · 2023 · Experimental Hematology
  39. A High-Throughput Cell-Based Screen Identified a 2-[(E)-2-Phenylvinyl]-8-Quinolinol Core Structure That Activates p53
    John Bechill, Rong Zhong, Chen Zhang, Elena Solomaha, Michael T. Spiotto · 2016 · PLoS ONE
  40. Structural And Computational Perspectives of Selectively Targeting Mutant Proteins
    Matt Coban, Sarah Fraga, Thomas R. Caulfield · 2020 · Current Drug Discovery Technologies
  41. An antibody‐free strategy for screening putative HDM2 inhibitors using crude bacterial lysates expressing GST‐HDM2 recombinant protein
    Barbara Costa, Agostina Francesca Grillone, Alessandra Salvetti, Silvia Rocchiccioli, Paola Iacopetti, Simona Daniele, Eleonora Da Pozzo, Pietro Campiglia, Ettore Novellino, Claudia Martini et al. · 2013 · Drug Testing and Analysis
  42. The transcriptional regulatory function of p53 is essential for suppression of mouse skin carcinogenesis and can be dissociated from effects on TGF‐β‐mediated growth regulation
    Roshini M. Ponnamperuma, Kathryn E. King, Tamador Elsir, Adam B. Glick, Geoffrey M. Wahl, Monica Nistér, Wendy C. Weinberg · 2009 · The Journal of Pathology
  43. Long-Term Survival Following Treatment with Antineoplastons for Colon Cancer with Unresectable Multiple Liver Metastases: Report of a Case
    Yutaka Ogata, HIDEAKI TSUDA, Keiko Matono, Tsutomu Kumabe, Hideki Saitsu, Hiroshi Hara, Yoshito Akagi, Yasumi Araki, Michio Sata, Kazuo Shirouzu · 2003 · Surgery Today
  44. Selecting the Right Targets for Cancer Therapy
    Miguel H. Bronchud · 2008 · Humana Press eBooks
  45. p53
    Xin Lü · 2012 · Elsevier eBooks
  46. Pharmacological Chaperones: Potential for the Treatment of Hereditary Diseases Caused by Mutations in G Protein‐Coupled Receptors
    Kenneth J. Valenzano, Elfrida R. Benjamin, Patricia René, Michel Bouvier · 2010 · Wiley eBooks
  47. Pharmacogenomics of the p53 tumor suppressor and its role in cancer chemoresistance
    Suxing Liu, Walter Robert Bishop, Bimal Dasmahapatra, Yaolin Wang · 2004 · Drug Development Research
  48. Refractory alveolar rhabdomyosarcoma in an 11-year-old male
    Cora A. Ricker, Andrew D. Woods, William Simonson, Melvin Lathara, Ganapati Srinivasa, Erin R. Rudzinski, Atiya Mansoor, Robert G. Irwin, Charles Keller, Noah Berlow · 2021 · Molecular Case Studies
  49. Primary sarcomas of the bladder and prostate: A genomic landscape study
    Dana J. Hariri, Dean Pavlick, Phillipe E. Spiess, Roger Li, Ashish M. Kamat, Petros D. Grivas, Neeraj Agarwal, Shilpa Gupta, Andrea Necchi, Gennady Bratslavsky et al. · 2025 · Pathology - Research and Practice
  50. Mutant p53 Regulates Pyruvate Dehydrogenase Kinase 1 ( PDK1 ) to Promote Proliferation and Migration in Breast Cancer
    Yan Ye, Zuli Ou, Cong Li, Qingyu Liao, Qian Zeng, Xiaoqian Ju, Dian Zhang, Yu Wei, Xiang Zhang, Jia‐Tao Zhang et al. · 2025 · Cancer Science
  51. C-Terminal p53 Palindromic Tetrapeptide Restores Full Apoptotic Function to Mutant p53 Cancer Cells In Vitro and In Vivo
    Robert Lance Fine, Yuehua Mao, Richard D. Dinnen, Ramon V. Rosal, Anthony J. Raffo, URI HOCHFELD, Patrick B. Senatus, Jeffrey N. Bruce, GWEN L. NICHOLS, Hsin Wang et al. · 2023 · Biomedicines
  52. Pyrimidine Triones as Potential Activators of p53 Mutants
    Maryam M.J. Fallatah, Özlem Demir, Fiona V. Law, Linda Lauinger, Roberta Baronio, Linda Hall, Elodie Bournique, Ambuj Srivastava, Landon Tyler Metzen, Zane Norman et al. · 2024 · Biomolecules
  53. TP53 mutations and MDM2 polymorphisms in breast and ovarian cancers: amelioration by drugs and natural compounds
    Rituraj Chakraborty, Anupam Dutta, Rupak Mukhopadhyay · 2025 · Clinical & Translational Oncology
  54. Heterogeneity of TP53 mutations necessitates differentiation with p53-rescue therapies
    Jiaqi Wu, Huaxin Song, Shujun Xiao, Min M. Lu · 2025 · Nature reviews. Cancer
  55. Establishment and characterization of human bladder cancer cell lines BexBra1, BexBra2, and BexBra4
    Camila Belfort Piantino, Juliana Moreira de Sousa-Canavez, Victor Srougi, Fernanda Aburesi Salvadori, Raphael Kato, Pedro Paulo Marino Rodrigues Ayres, Miguel Srougi, Luiz Heraldo A. Camara-Lopes, Gilka Jorge Fígaro Gattás, Cíntia Fridman et al. · 2009 · In Vitro Cellular & Developmental Biology - Animal
  56. Recombinant GnRH-p53 protein sensitizes breast cancer cells to 5-fluorouracil-induced apoptosis in vitro and in vivo
    Yi Wei Lu, Zhi‐Song Zhang, Zhenwen Yan, Li Chen, Weimin Deng, Michael T. Lotze, Zhou Wang, Xinli Lin, Luyuan Li · 2013 · APOPTOSIS
  57. Relative Stability of Wild-Type and Mutant p53 Core Domain: A Molecular Dynamic Study
    Leyla Rohani, Derrick Jerone Morton, Xiaoqian Wang, Jaideep Chaudhary · 2015 · Journal of Computational Biology
  58. p53-dependent cell cycle checkpoint after DNA damage and its relevance to PARP1
    Tadashige Nozaki, Mitsuko Masutani · 2018 · Research and Review Insights
  59. Improving Reporter Gene Assay Methodology for Evaluating the Ability of Compounds to Restore P53 Activity
    Xinle Han, Jun Du, Dandan Shi, Lingjie Li, Dandan Li, Kun Zhang, Su-Wen Lin, Jingzhong Zhu, Zoufang Huang, You Zhou et al. · 2022 · International Journal of Molecular Sciences
  60. ARHGAP44-mediated regulation of the p53/C-myc/Cyclin D1 pathway in modulating the malignant biological behavior of osteosarcoma cells
    Shizhe Li, Jiancheng Xue, He Zhang, Guanning Shang · 2023 · Journal of Orthopaedic Surgery and Research
  61. Mutant p53 reactivators protect breast cancer cells from ferroptosis
    Dewmi Sandaru Rathnayake, Samkeliso Dlamini, Kadry Elkalawozgy, L. M. Viranga Tillekeratne, William R. Taylor · 2024 · Cell Biochemistry and Function
  62. The Oncogenic Activity of p53 Mutants
    Alex Sigal, Varda Rotter · 2007 · Springer eBooks
  63. Drugs that Suppress Proliferation
    Georg F. Weber · 2015 · Springer eBooks
  64. Modes of p53 Interactions with DNA in the Chromatin Context
    Vladana B. Vukojević, Tatiana Yakovleva, Georgy Ya. Bakalkin · 2010 · Molecular biology intelligence unit
  65. La réactivation par translecture du gènep53possédant une mutation non-sens induit l’apoptose de cellules cancéreuses
    Célia Floquet, Jean‐Pierre Rousset, Laure Bidou · 2011 · médecine/sciences
  66. Understanding Racial Differences In Colorectal Cancer Aids In Individualized Medicine
    Upender Manne · 2007 · Future Oncology
  67. Therapeutic Strategies Based on Pharmacological Modulation of p53 Pathway
    Andrei V. Gudkov · 2005 · Springer eBooks
  68. Incorporation of Novel therapies for the treatment of acute myeloid leukemia: a perspective
    Julian A. Waksal, Martin S. Tallman · 2021 · Leukemia & lymphoma/Leukemia and lymphoma
  69. HROP68: A rare case of medullary pancreatic cancer—characterization and chemosensitivity of the first patient-derived cell line
    Jens von den Driesch, Jana Mathea Flöttmann, Friedrich Prall, Christina Susanne Mullins, Michael Linnebacher, Florian Bürtin · 2023 · Frontiers in Oncology
  70. Construction of a Reporter System for Fine Assessment of the p53 Activity in Cultured Cells
    S. M. Strunina, Alexey V. Ivanov, Peter M. Chumakov · 2003 · Molecular Biology
  71. CRISPR/Cas9 gene editing in gastric cancer: Mechanisms, advances, and therapeutic potential
    Grigorios Christodoulidis, Dimitra Bartzi, Kyriaki Tsagkidou, Alexandra Dimaki, Lydia Lazaridou, Kalliopi Vakalou, Konstantinos Eleftherios Koumarelas, Dimitriοs Schizas · 2025 · World Journal of Gastrointestinal Pathophysiology
  72. Thiol-Epoxy Click Chemistry: Neutral Quaternary Phosphonium-Promoted Weak Catalysis for Alkylation of Thiols
    Silei Ye, Fang Zhang, Jing Zhao, Yunji Yang, Yanren Zhu, Mengxian Yang, Yushun Zhang, Dongbo Zhao, Hongbin Zhang, Jingbo Chen · 2025 · ACS Sustainable Chemistry & Engineering
  73. Breast Cancer Therapy by Small-Molecule Reactivation of Mutant p53
    Simon H. Slight, Salman M. Hyder · 2025 · Current Oncology
  74. Fibrillarin: bridging ribosome biogenesis and apoptosis in cellular stress and disease
    Zhuoyuan Zhang, Min Zhang, Zixuan Cao, Haoyan Zhao, Xin Li, Peng Luo · 2026 · APOPTOSIS
  75. Nanoparticle-mediated radiosensitization in colorectal cancer radiation therapy: A narrative review on mechanisms, clinical translation, and future perspectives
    Sina Taghvimi, Elahe Soltani Fard, Alireza Baghrobehbahani, Mohsen Shafiee, Vahid Zarezadeh, Mina Pourhabib Mamaghani, Mohammadreza Nazarian, Nahid Chegeni, Ahmad Movahedpour, Pegah Mousavi et al. · 2026 · Applied Radiation and Isotopes
  76. p53-Reactivating Molecules as Research Tools and Anticancer Drugs
    Vera V. Grinkevich, Andreas Warnecke, Galina Selivanova · 2012 · Springer eBooks
  77. Regulation of p53 Activity and Associated Checkpoint Controls
    Sean M. Post, Alfonso Quintás‐Cardama, Guillermina Lozano · 2009 · Humana Press eBooks
  78. Aspergillus fumigatus-derived demethoxyfumitremorgin C inhibits proliferation of PC3 human prostate cancer cells through p53/p21-dependent G1 arrest and apoptosis induction
    Young‐Sang Kim, Sun Joo Park · 2021 · Fisheries and aquatic sciences
  79. Radio-protective efficacy of Gymnema sylvestre on Pangasius sutchi against gamma (60Co) irradiation
    Pamela Sinha, Kantha Devi Arunachalam, Santhosh Kumar Nagarajan, Thirumurthy Madhavan, Arumugam Radhakrishnan Jayakumar, Mohamed Saiyad Musthafa · 2021 · International Journal of Radiation Biology
  80. An unusual form of BRAF‐V600E mutated hairy cell neoplasm with clinical resistance to BRAF inhibition: Challenging precision medicine
    Andrea Marra, Alessia Santi, Alessandra Pucciarini, Alessandra Venanzi, Luca De Carolis, Francesco F. Zaja, Stefano Ascani, Vincenzo Canzonieri, Stelvio Ballanti, Brunangelo Falini et al. · 2024 · American Journal of Hematology
  81. Neuroblastoma response to RAS-MAPK inhibitors and APR-246 (eprenetapopt) co-treatment is dependent on SLC7A11
    Vid Mlakar, Ina Oehme, Laurence Lesne, Sara Najafi, Marc Ansari, Fabienne Gumy‐Pause · 2024 · Frontiers in Oncology
  82. Combination therapy in cancer: The potential of tetrandrine as a polytherapy for acute myeloid leukemia
    Daniel L. Barry, Anoop Kumar Enjeti, Lisa F. Lincz, Kathryn Anne Skelding · 2025 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
  83. Current Strategies for Cancer Gene Therapy
    Yufang Zuo, Xiaofang Ying, Hui Wang, Wen Ye, Xiangqi Meng, Hou–Yong Yu, Yi Zhou, Wuguo Deng, Wenlin Huang · 2011 · InTech eBooks
  84. Mutant p53 Reactivation as a Novel Strategy for Cancer Therapy
    Galina Selivanova, Vladimir J.N. Bykov, Klas G. Wiman · 2005 · Springer eBooks
  85. Molecular Chaperone Inducers Facilitate the Functional Restoration of Temperature-sensitive Mutant p53 Protein
    DAISUKE KAWASHIMA, Minoru Soga, Rika Takeuchi, Hideki Matsumoto, Kenzo Ohtsuka · 2010 · Thermal Medicine
  86. Possible involvement of NO in the stimulating effect of pifithrins on survival of hemopoietic clonogenic cells
    S. Ya. Proskuryakov, A. G. Konoplyannikov, O. A. Konoplyannikova, Л. И. Шевченко, Yu. G. Verkhovskii, Anatoli F. Tsyb · 2009 · Biochemistry (Moscow)
  87. Novel anti-cancer compounds: Structure-based discovery of chemical chaperons for p53
    Kuwata · 2009 · Oncology Reports
  88. P53: Its Role in Carcinogenesis And Also A Novel Target for Anti-Cancer Therapy
    Sujan Narayan Agrawal · 2016 · IOSR Journal of Dental and Medical Sciences
  89. GDF15 as a Novel Biomarker for Monitoring Danusertib Activity
    Patrizia Carpinelli, Paolo Cappella · 2012 · Journal of Molecular Biomarkers & Diagnosis
  90. Caractérisation génomique des carcinomes épidermoïdes de la tête et du cou : impact et enjeux pour la prise en charge thérapeutique
    Esma Saâda-Bouzid, Gerard Alain Milano, Juliette Thariat · 2018 · Bulletin du Cancer
  91. Targeting TP53 Mutations in Myelodysplastic Syndromes
    David Andrew Sallman · 2018 · The Hematologist
  92. EXABS-147-AML How Do We Overcome Resistance to Venetoclax
    Kapil Saxena, Bing Z. Carter, Marina Y Konopleva · 2022 · Clinical Lymphoma Myeloma & Leukemia
  93. The yin and yang of cancer therapeutics.
    Miguel H. Bronchud · 2005 · PubMed
  94. MicroRNA-29a plays a prominent role in PRIMA-1Met-induced apoptosis in ovarian cancer cells
    Nilüfer İmir · 2020 · Archives of Biological Sciences
  95. Cellular signaling in glioblastoma: A molecular and clinical perspective
    Debarati Ghosh, Brett Pryor, Nancy Jiang · 2024 · International review of cytology
  96. Experimental kinetic mechanism of P53 condensation-amyloid aggregation
    Silvia Susana Borkosky, Ramon Peralta-Martinez, Alicia Armella-Sierra, Sebastián Esperante, Leonardo Lizárraga, Javier García‐Pardo, Salvador Ventura, Ignacio Enrique Sanchez, Gonzalo de Prat Gay · 2025 · Biophysical Journal
  97. p53 mutation-associated prognosis across cancer types underlines hematological malignancy as an applicable cancer type to p53-rescue therapy
    Shujun Xiao, Jiaqi Wu, Kai Wei Tan, Sujiang Zhang, Yuting Dai, Jiarui Wu, Jiale Wu, Xinle Han, Derun Zheng, Xin Wang et al. · 2025 · Fundamental Research
  98. Carvacrol-induced apoptosis via tumor suppressor gene activation and oxidative stress modulation in a rat model of breast cancer
    Amany Elwakkad, Amina A. Gamal el Din, Mohamed A. Hebishy, Howida S. Abou-Seif · 2025 · Discover Oncology
  99. AI-Guided Conformational Dynamics of p53 L1 Loop Reveal an Allosteric Switch Regulating DNA Binding and Cancer Hotspots
    Pablo Navarro Acero, Ming‐Hong Hao, Karan Kapoor · 2026 · Journal of Chemical Information and Modeling
  100. Reactivating p53 mutants selectively in patients
    Shuo Chen, H. Michael Shepard, Min Lu · 2026 · Cancer Cell